

1 **The Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort**
2 **study**

3
4 **Authors:** *Stefan Rohner^{1,2}, *Rebekka Schnepfer^{2,3}, Gunther Meinlschmidt^{3,4}, Rainer
5 Schaefer^{1,2}, Michael Mayr^{1,5}, ♦Katrin Bopp^{1,5}, ♦Andrea Meienberg^{1,5}

6 * shared first authorship

7 ♦ shared last authorship

8
9 **Author Affiliations:**

10 ¹ University of Basel, Faculty of Medicine, Basel, Switzerland

11 ² University Hospital Basel, Department of Psychosomatic Medicine, Basel, Switzerland

12 ³ University Hospital Basel, Department of Digital and Blended Psychosomatics and
13 Psychotherapy, Basel, Switzerland

14 ⁴ University of Trier, Department of Clinical Psychology and Psychotherapy, Trier, Rheinland-
15 Pfalz, Germany

16 ⁵ University Hospital Basel, Medical Outpatient Clinic, Basel, Switzerland

17
18 **Authors' ORCID-IDs:**

19 Stefan Rohner: <https://orcid.org/0000-0002-4812-6433>

20 Rebekka Schnepfer: <https://orcid.org/0000-0002-5415-5943>

21 Gunther Meinlschmidt: <https://orcid.org/0000-0002-3488-193X>

22 Rainer Schaefer: <https://orcid.org/0000-0002-3077-7289>

23 Michael Mayr: <https://orcid.org/0000-0002-1962-8186>

24 Katrin Bopp: <https://orcid.org/0000-0001-6398-4375>

25 Andrea Meienberg: <https://orcid.org/0000-0002-0751-2469>

26
27 **Short title:** BALCoS study protocol

28
29 **Protocol Version:** 1.4

30
31 **Sponsors:** Prof. Dr. med. Rainer Schaefer, PD Dr. med. Michael Mayr

32
33 **Principle Investigator:** Prof. Dr. Gunther Meinlschmidt, gunther.meinlschmidt@unibas.ch

34
35 **Co-Investigators:** Dr. rer. nat. Rebekka Schnepfer, Dr. med. Andrea Meienberg, Dr. med.
36 Katrin Bopp

37
38 **Corresponding Author:** Dr. med. Andrea Meienberg, andrea.meienberg@usb.ch

39
40 **Submitting Author:** Stefan Rohner, stefan.rohner@usb.ch

41
42 **Number of figures:** 1

43
44 **Number of tables:** 3

45
46 **Word count:** 4625

47 **ABSTRACT**

48 **Introduction** The recent severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-
49 2) pandemic had a devastating global impact. Many people suffered from coronavirus disease
50 2019 (COVID-19) and some experienced persistent symptoms interrupting their lives even
51 further. The World Health Organization (WHO) defined the condition of these persistent
52 symptoms as post-COVID-19 condition (PCC). The most prevalent PCC symptoms are fatigue,
53 dyspnea, sleep disturbances, coughing, anosmia and ageusia, chest pain, and headaches.
54 This article describes the protocol of the Basel Long COVID Cohort Study (BALCoS), which
55 aims at fostering understanding of PCC and investigating underlying mechanisms for the
56 development and course of the condition by focusing on participants' health status and
57 symptoms with repeated measures over one year.

58 **Methods and analysis** BALCoS is a prospective single site cohort study. Inclusion criteria are
59 a confirmed PCC diagnosis according to WHO or a subjective attribution of persistent
60 symptoms to PCC, proficiency in German to follow study procedures, and at least 18 years of
61 age. It comprises blood sample collections, standardized neurocognitive and psychometric
62 tests, physical performance measures, and ecological momentary assessments (EMAs).
63 Standardized tests and EMAs are administered at baseline (BL), and at 3-, 6-, and 12-months
64 follow-up. At BL and 12-month follow-up, physical performance and neurocognitive abilities are
65 assessed. Participants provide blood samples at BL. The study is exploratory in nature and a
66 sample size of at least 120 participants is targeted. The study is part of a larger Horizon Europe
67 Long COVID project combining mechanistic, clinical, and intervention studies within an
68 interdisciplinary European research consortium.

69 **Ethics and dissemination** The Ethics Commission of Northwest and Central Switzerland
70 approved the study (BASEC-ID: 2023-00359), which is registered at ClinicalTrials.gov (ID:
71 NCT05781893). All participants provide written informed consent. Key results from the study
72 will be published in peer-reviewed journals.

73 **Funding Details** BALCoS is primarily funded by the Swiss State Secretariat for Education,
74 Research and Innovation (SERI) under contract number 22.00094 in the context of the
75 European Union's Horizon Europe research and innovation program under grant agreement
76 No. 101057553.

77
78 **Keywords:** cohort study, SPIROS, post-COVID, long COVID, post-acute sequelae of SARS-
79 CoV-2, PASC, study protocol

80
81 **Conflict of Interest Statement**

82 GM received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia
83 Bangerter-Rhyner-Stiftung under projects no. PC 28/17 and PC 05/18, from Health Promotion
84 Switzerland under project no. 18.191/K50001, from the Swiss Heart Foundation under project
85 no. FF21101, from the Research Foundation of the International Psychoanalytic University
86 (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation
87 (SNSF) under project no. 100014_135328, from the German Federal Ministry of Education and
88 Research under budget item 68606, from the Hasler Foundation under project No. 23004, from
89 SERI under contract number 22.00094 in the context of a European Union (Horizon Europe)
90 research consortium "Long COVID" (funding number: 101057553) and from Wings Health in
91 the context of a proof-of-concept study. GM is a co-founder and shareholder of Therayou AG,
92 active in digital and blended mental healthcare. GM receives royalties from publishing
93 companies as author, including a book published by Springer, and an honorarium from
94 Lundbeck for speaking at a symposium. Furthermore, GM is compensated for providing
95 psychotherapy to patients, acting as a supervisor, serving as a self-experience facilitator
96 ('Selbsterfahrungsleiter'), and for postgraduate training of psychotherapists, psychosomatic
97 specialists, and supervisors.

98 RaS received funding from Promotion Santé Suisse (Gesundheitsförderung Schweiz) under
99 contract no. 18.191/ K50001, from the Health Department Basel-City, from SERI under contract
100 number 22.00094 in the context of a European Union (Horizon Europe) research consortium
101 "Long COVID" (funding number: 101057553), and from Wings Health in the context of a proof
102 of concept study. RaS is coeditor of the German AWMF S3-Guidelines on Functional

103 Complaints and contributed to the German guidelines on irritable bowel syndrome, and on
104 Lyme Borreliosis. RaS is chairman of the Basel Institute for Psychosomatic Medicine (BIPM),
105 and founder and managing director of the Psychosomatic and Psychosocial Services GmbH,
106 that develops and implements psychosomatic and psychosocial training and continuing
107 education programs. RaS is member of the Swiss Academy of Psychosomatic and
108 Psychosocial Medicine (SAPPM) – where he is member of the Scientific Advisory Board, of
109 the Société Médicale Suisse d’Hypnose (SMSH), of the Dt. Kollegium für Psychosomatische
110 Medizin (DKPM), of the Dt. Gesellschaft für Psychosomatische Medizin und Ärztliche
111 Psychotherapie (DGPM), and of the German Balint Society (DBG). RaS serves as spokesman
112 of DKPM and DGPM for Consultation and Liaison Psychosomatics. He is a member of the
113 board of trustees of the Foundation Psychosomatic and Social Medicine (Ascona Foundation).
114 MM served as a consultant for AstraZeneca, Boehringer Ingelheim, Bayer and received
115 unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb Pfizer, Daiichi
116 Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis, and Viatrix.
117 ReS received funding from SERI under contract number 22.00094 in the context of a European
118 Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553).
119 AM received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb
120 Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis, and
121 Viatrix.

122

123 **Strengths and Limitations**

- 124 • Repeated assessments are expected to inform about the course of illness
125 progression and development within routine medical care.
- 126 • A broad array of participant-reported outcomes strengthens participant perspective of
127 symptoms.
- 128 • The duration of data collection and the number of questionnaires might influence
129 questionnaire completion and adherence.
- 130 • Planned follow-up of 12 months limits conclusions regarding long-term outcome.
- 131 • The exploratory nature of the study allows to explore risk factors and associations,
132 but not causality.

133 **INTRODUCTION**

134 In early 2020, the coronavirus disease 2019 (COVID-19), caused by the severe acute
135 respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. As the
136 pandemic progressed, it became apparent that the disease not only causes acute symptoms
137 but can also lead to long-term complaints (sometimes termed “long COVID”, in the following
138 referred to as “post-COVID-19 condition”, PCC). According to the definition of the World Health
139 Organization (WHO), PCC is defined as symptoms occurring in individuals with a history of
140 confirmed or suspected SARS-CoV-2 infection, lasting for at least two months, usually within
141 three months from the onset of the acute infection, that cannot be explained by an alternative
142 diagnosis (1). Generally, symptoms are heterogeneous (2) and present across multiple organ
143 systems. Common symptoms include fatigue, dyspnea, sleep disturbances, coughing,
144 anosmia and ageusia, chest pain, headaches (3). According to a meta-analysis conducted in
145 March 2022, the prevalence of PCC ranges from 7.5% to 41% in non-hospitalized adults and
146 averages 37.6% in hospitalized adults (4). Due to methodological differences in the published
147 literature, prevalence rates vary considerably and numbers are difficult to reliably estimate.
148 Even though some risk factors of PCC could be identified, such as virus variant, female gender,
149 hypertension, smoking, obesity, and comorbid diseases (5-9), the etiology of PCC is still
150 unclear (10, 11). Several hypotheses have been proposed, such as immune dysregulation
151 (12), microbiota dysbiosis which affects the microbiota and virome, including the persistence
152 of SARS-CoV-2 (13), autoimmunity and primed immune cells by molecular mimicry (14),
153 microvascular coagulation with endothelial dysfunction (15), and dysfunctional signaling in the
154 brainstem and/or vagus nerve (16). These findings show that biomedical components have
155 been the focus of PCC research. However, psychological factors are also increasingly
156 considered and have been shown to play an important role (17). These factors are incorporated
157 into psychotherapeutic treatment approaches (18). Due to insufficient understanding of the
158 mechanisms that underlie the development of PCC, treatment options are currently limited and
159 mainly focus on symptom management. This lack of understanding potentially contributes to
160 those affected by PCC experiencing feelings of helplessness, frustration, being
161 misunderstood, worry due to the uncertain course of the disease, and a sense of losing control
162 over their lives (19). A better understanding of the pathogenesis, risks, and protective factors
163 of PCC would help to improve health care and support of people affected with PCC (20, 21).
164 Here we provide the protocol of the Basel Long COVID Cohort study (BALCoS), which aims
165 to investigate and better understand PCC, its symptoms and course, and to illuminate the
166 underlying multifactorial mechanisms of the condition by collecting a broad biopsychosocial
167 spectrum of data over the course of one year. Participants complete a set of assessments that
168 include the collection of sociodemographic and clinical data, biomarkers, neurocognitive
169 testing, psychometric questionnaires, ecological momentary assessments (EMAs), and
170 measures of physical performance. This research serves as a basis for planning future
171 measures and provides information on clinically relevant factors for health care professionals.
172 From this research it may be possible to derive factors that positively influence the quality of
173 care of patients and their overall quality of life.

174

175 **METHODS AND ANALYSIS**

176

177 **Study Design and Setting**

178 BALCoS is a registry-based, single-center, prospective, observational cohort study. The study
179 site is located at the Medical Outpatient Clinic of the University Hospital Basel (UHB) and
180 participants are recruited from patients attending the specialized PCC consultation service at
181 the UHB. In addition, study participation is open to individuals from consultation services and
182 clinics outside the UHB and individuals who respond to study advertisements. Written consent
183 is required from all participants.


184

185 **Study Timeline**

186 Recruitment started in February 2023, with the first participant enrolled in April 2023. The study
187 is intended to extend beyond the current SERI-funded research period, which runs until May

188 2026 to allow for further data collection and analysis, as well as continued scrutiny of the
 189 research questions, including changes in PCC over time (see Figure 1).
 190

191 **Figure 1.** Timeline of the Basel Long COVID Cohort Study.



192 Note: SERI = State Secretariat for Education, Research, and Innovation; COVID = coronavirus disease.
 193

194 **Study Schedule**

195 Participants are asked to give informed consent to the inclusion of all their data from previous
 196 medical examinations that could be relevant to their PCC symptoms. Further, they are asked
 197 to agree that the data collected in the study can be used for routine clinical care. Participants
 198 not recruited from the UHB PCC clinic provide this information in an enrollment interview, after
 199 signing the informed consent form. An overview of all clinical information collected at the
 200 baseline interview and routine clinical examination can be found in the supplemental material.
 201 At baseline (BL) and T3, participants complete psychometric measures and neurocognitive
 202 tests on a computer, tablet, or similar device. If the BL assessment is too exhausting for one
 203 visit, a second visit can be arranged to complete the neurocognitive test battery and measures
 204 of physical performance (marked with “(x)” in Table 1). Participants can choose to complete
 205 the study remotely, if travelling to the study site is not feasible due to health concerns or
 206 symptom burden. These participants complete the study as planned, except for the completion
 207 of physical performance measures, neurocognitive assessments, and blood sample collection
 208 at BL. Remote participants receive a link by email to complete the psychometric measures for
 209 BL and T3 online at home. At T1 and T2, all participants (remote and in-person) receive a link
 210 by email to a battery of psychometric questionnaires to complete online at home. One day after
 211 completing each data collection point (BL, T1, T2, and T3), participants receive a link via text
 212 message at 6 p.m. directing them to the EMA questions. These 8 EMA questions are answered
 213 over ten consecutive days. A detailed summary of the study plan is provided in Table 1.
 214

215 **Table 1.** Outcome measures and assessment schedule.
 216

	Outcome measure	BL		T1	T2	T3
		1	2			
0	Oral and written information, written consent, screening of inclusion and exclusion criteria	x				
1	Blood samples*	x				
2	Neurocognitive assessment: Central Nervous System Vital Signs (CNSVS) *	x	(x)			x
3	Physical performance measures*					
a	6-minute walking test	x	(x)			x
b	Jamar dynamometer	x	(x)			x
c	1-minute sit-to-stand test (STS-60)	x	(x)			x
4	Psychometric questionnaires					
a	Functional Capacity: World Health Organization Disability Assessment Schedule (WHODAS 2.0)	x		x	x	x

b	Visual Analogue Scales (VASs): quality of life, symptom intensity, functional impairment, work ability	x		x	x	x
c	Quality of Life: Quality-of-Life-8 (EuroHIS QOL-8)	x		x	x	x
d	Somatic Symptom Severity: Patient Health Questionnaire (PHQ-15)	x		x	x	x
e	Somatic Distress: Somatic Symptom Disorder – B Criteria Scale (SSD-12)	x		x	x	x
f	Depression : Patient Health Questionnaire Depression Scale (PHQ-8)	x		x	x	x
g	Anxiety: Generalized Anxiety Disorder Questionnaire (GAD-7)	x		x	x	x
h	Resilience: Resilience Scale (RS-11)	x		x	x	x
i	Insomnia: Insomnia Severity Index (ISI)	x		x	x	x
j	Fatigue : Chalder Fatigue Scale (CFS)	x		x	x	x
k	Stress: Perceived Stress Scale (PSS-10)	x		x	x	x
6	Ecological momentary assessments (EMAs; 8 daily questions for 10 consecutive days after BL, T1, T2, T3)		x	x	x	x

217 Note: BL = Baseline

218 *Measurements not completed by remote participants

219

220 Sampling procedure and selection

221 Enrollment is based on the inclusion criteria (see Table 2) and recruitment is carried out by the
222 study team which includes physicians, psychologists, psychotherapists, and study nurses.

223

224 **Table 2.** Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
Confirmed PCC diagnosis according to WHO or subjective attribution of persistent symptoms to PCC	Lack of general understanding of the study procedures
At least 18 years of age	Rejection of consent to participate
Adequate knowledge of German	

225 Note: PCC = post-COVID-19 condition

226

227 Until June 2024, only patients attending the PCC clinic at UHB were recruited. Due to
228 recruitment difficulties, recruitment was expanded from July 2024 to include patients from other
229 specialized consultation services or clinics in the broader Basel area with physician-based
230 diagnosis. From September 2024 onward, individuals with PCC symptoms and subjective
231 attribution of their persistent symptoms to PCC have been recruited as well. The study is
232 advertised in other specialized and outpatient clinics, general practitioners' offices, on public
233 transportation, at conferences and symposia, mailing lists, and via social and other digital
234 media. All potential participants are screened for inclusion and exclusion criteria. The study
235 investigator (or their nominee) obtains written informed consent from all study participants.
236 Study information is presented by phone or video call if travel for the sole purpose of face-to-
237 face recruitment is not possible. As part of the recruitment and informed consent process, the
238 investigators (or their designees) explain to each participant the nature of the study, its
239 purpose, the procedures involved, the expected duration, the potential risks and benefits, and
240 any inconvenience that may be involved. Each participant is informed that participation in the
241 study is voluntary, that they may withdraw from the study at any time, and that withdrawal of
242 consent will not affect their subsequent medical care. No formal sample size calculation and
243 or power analysis has been performed prior to recruitment. The target sample size is 120
244 participants for the funded period. The rationale for no prior sample size calculation is based
245 on the exploratory nature of the study. The target sample size is based on heuristics and

246 estimates by the study team regarding of the number of people that sought help at the PCC
247 clinic in 2021 and 2022.

248

249 **Horizon Europe Long COVID consortium**

250 The BALCoS study is part of the Horizon Europe Long COVID project. The consortium takes
251 a biopsychosocial perspective on PCC and aims to gain a more comprehensive understanding
252 of PCC to identify mechanisms, processes, and biomarkers of the condition, and to develop
253 management strategies and treatment approaches. The research efforts include cohort
254 studies, biomechanistic studies, and (digital) intervention studies. BALCoS is one of the cohort
255 studies being conducted. Participants in the BALCoS cohort are asked to provide blood
256 samples for the consortium's biomechanistic studies.

257

258 **Blood samples and assessments¹**

259 **Blood Samples**

260 At BL, participants provide blood samples for on-site analysis and for analysis by the
261 consortium (see Table 3). These samples will be analyzed for genomic and human leukocyte
262 antigen (HLA) typing (plasma), COVID-19 antibody profiling (serum), lipidome (serum),
263 autoantibody epitopes (serum), and coagulation analyses (citrated plasma). Due to limited
264 resources, for some parameters only a sub-sample of enrolled participants will be sent and
265 analyzed. Participants may refuse genomic analyses and still be included in the study.

266

267 **Table 3.** Overview of blood sample collection.

Blood samples for on-site analysis	Blood samples for the consortium
RNA tubes for genetic analyses (optional)	EDTA plasma (for genetic analyses; optional)
EDTA plasma	Citrated plasma
Serum	Serum

268 Note: RNA = Ribonucleic Acid, EDTA = Ethylenediaminetetraacetic Acid.

269

270 **Neurocognitive Testing**

271 *CNS Vital Signs* (CNSVS, 22) is a computerized neurocognitive test battery that was
272 developed as a routine clinical screening instrument. It consists of seven scientifically valid and
273 reliable neuropsychological tests. The tests are verbal and visual memory, finger tapping,
274 symbol digit coding, the Stroop Test, a test of shifting attention, and the continuous
275 performance test. Completion of the tests takes 40-50 minutes. The psychometric properties
276 of the CNSVS tests have been shown to be comparable to the interview-based conventional
277 neuropsychological tests from which they were derived (23).

278

279 **Psychometric Questionnaires**

280 *Visual Analogue Scales* (VAS, 24) – Participants answer 4 questions on a VAS with a 10-point
281 Likert scale rating slider ranging from 1 to 10. The questions cover symptom intensity (“How
282 do you currently rate the intensity of your symptoms?”, 10 = it can't be worse), functional
283 impairment (“How do you currently rate the impairment caused by your symptoms in everyday
284 life?”, 10 = it can't be worse), quality of life (“How would you rate your current quality of life?”,
285 10 = it can't be better), and work capacity (10 = full work capacity). For work capacity,
286 participants indicate their current work capacity (“current workload in % per week”) and their
287 maximum work capacity before the onset of PCC symptoms on a scale from 0% - 100%
288 (“Regular workload before symptoms started in % per week”).

289 *Functional Capacity* – World Health Organization Disability Assessment Schedule (WHODAS
290 2.0): The WHODAS 2.0 assesses and classifies disability due to health problems during the 4
291 previous weeks. The 12-item version is used in this study (25). An example item would be “In
292 the past 4 weeks, how much difficulty have you had walking a long distance such as one

¹ All study materials including (computerized) measurements are in German only.

293 kilometer (or equivalent)?". Items are answered on a 5-point Likert scale ranging from 0 =
294 "none" to 4 = "extreme or impossible".

295 *Quality of Life* – EuroHIS Quality-of-Life-8 (QOL-8, 26): This 8-item instrument assesses
296 quality of life and perceived health during the 4 previous weeks, e.g. by asking "Do you have
297 enough energy to cope with everyday life?". Items are answered on a 5-point Likert scale, with
298 wording varying between questions (e.g., from "very dissatisfied" to "very satisfied").

299 *Somatic Symptom Severity* – Patient Health Questionnaire (PHQ-15, 27): The PHQ-15
300 assesses the severity of somatic symptom over the previous 4 weeks. Participants are asked
301 how much they felt affected by their symptoms, (e.g., back pain). Items are answered on a 3-
302 point Likert scale ranging from 0 = "not bothered at all" to 2 = "bothered a lot".

303 *Somatic Distress*: Somatic Symptom Disorder–B Criteria Scale (SSD-12, 28):The SSD-12
304 assesses psychological features of somatic disorders with four questions each on the cognitive
305 (disproportionate and persistent thoughts about the seriousness of one's symptoms), affective
306 (health anxiety), and behavioral (excessive time and energy devoted to these symptoms or
307 health concerns) dimensions. Items are answered on a 5-point Likert scale ranging from 0 =
308 "never" to 4 = "very often".

309 *Depression* – Patient Health Questionnaire Depression Scale (PHQ-8, 29): The PHQ-8
310 assesses the severity of depressive symptoms according to the 4th Edition of the Diagnostic
311 and Statistical Manual of Mental Disorders (DSM-IV;30). Participants are asked whether they
312 have been bothered by symptoms typical for depression (e.g., by having little interest or
313 pleasure in doing things) in the past few weeks. Items are answered on a 4-point Likert scale
314 ranging from 0 = "not at all" to 3 = "almost every day".

315 *Anxiety* – Generalized Anxiety Disorder Questionnaire (GAD-7, 31): The GAD-7 measures
316 anxiety. It assesses whether the participant has been bothered by complaints related to anxiety
317 in the past 2 weeks (e.g., by asking about difficulties in relaxing). Items are answered on a 4-
318 point Likert scale ranging from 0 = "not at all" to 3 = "almost every day".

319 *Resilience* – 11-item Resilience Scale (RS-11, 32): The RS-11 asks about general resilience
320 to life events, e.g. "I feel that I can handle many things at the same time.". Items are answered
321 on a 7-point Likert scale ranging from 1 = "strongly agree" to 7 = "strongly disagree".

322 *Insomnia* – Insomnia Severity Index (ISI, 33): The ISI assesses sleep problems. Items are
323 answered on a 5-point Likert scale regarding severity over the past 2 weeks, with wording
324 varying between questions (e.g., from 0 = "very dissatisfied" to 4 = "very satisfied").

325 *Fatigue* – 11-item Chalder Fatigue Scale (CFS, 34): The CFS assesses fatigue on a mental
326 subscale (e.g., by asking "Do you have difficulty concentrating?" and a physical subscale (e.g.,
327 by asking "Do you need to rest more?"). Items are answered on a 4-point Likert scale ranging
328 from 0 = "better than usual" to 3 = "much worse than usual".

329 *Stress* – Perceived Stress Scale (PSS-10, 35): The PSS assesses the experience of
330 psychological stress in the last 4 weeks. It consists of 10 items, e.g., "In the last month, how
331 often have you been upset about something that happened unexpectedly?". Items are
332 answered on a 5-point Likert scale ranging from 1 = "never" to 5 = "very often".

333 *EMA Questions* – After each data collection point (BL, T1, T2, T3), participants answer 8 daily
334 EMA questions for 10 consecutive days. Questions 1-5 are based on the Screening Tool for
335 Psychological Distress (STOP-D, 36), question 6 is based on the EQ-5D (37, 38), question 7
336 is based on the Single Item Mindfulness Scale (SIMS; 39), and question 8 is based on the
337 Single Item Self Compassion Scale (SISC; 40). The questions are completed in the Research
338 Electronic Data Capture (REDCap, 41) on a 10-point Likert scale ranging from 0 = "not at all"
339 to 9 = "severely". Namely, these questions are: "In the last 24h, how much have you been...

- 340 1) ...bothered by feeling sad, down, or uninterested in life?
- 341 2) ...bothered by feeling anxious or nervous?
- 342 3) ...bothered by feeling stressed?
- 343 4) ...bothered by feeling angry?
- 344 5) ...bothered by not having the social support you feel you need?
- 345 6) ...bothered by difficulties in carrying out your daily activities?
- 346 7) ...fully in the moment, accepting it as it is?
- 347 8) ...high levels of self-compassion for yourself?"

348

349 Measures of physical performance

350 *Grip strength* – Jamar dynamometer (42): Sitting in a chair, the participant is instructed to
351 squeeze the hydraulic grip strength measuring device with one hand, while the other arm rests
352 in their lap. The test is repeated three times for each hand, first for the dominant hand, then
353 for the non-dominant hand. The best value (in kg) for each hand is recorded. Injuries to one or
354 both hands are also recorded.

355 *Functional exercise capacity* – 6-minute walking test (43): The distance (total meters), that a
356 participant can walk in six minutes is measured. Pulse and oxygen saturation are assessed at
357 baseline, immediately after finishing the test, and 2 minutes after finishing the test, using a
358 pulse oximeter. Pre- and post-exercise comfort is rated on a 5-point Likert scale ranging from
359 1 = “very poor” to 5 = “very good”. After the test, perceived respiratory and leg exertion is
360 assessed using the Borg Category-Ratio (CR) 10 Scale ranging from 0 = “no exertion” to 10 =
361 “maximum exertion” (44).

362 *Muscular endurance* – Sit-to-Stand Test (STS-60, 45): The STS-60 assesses the number of
363 sit-to-stand cycles that the participant can complete in 60 seconds without using their hands
364 for support. Oxygen saturation at the end of the test is assessed using a pulse oximeter.

365

366 **Data collection and management**

367 Data are mainly collected through electronic means: Psychometric questionnaires, EMAs and
368 neurocognitive assessments in the form of online surveys or computerized assessments. Data
369 collection for physical performance measures is paper based. Electronic data capture is done
370 within the REDCap electronic case report form (eCRF). Paper-based data will be entered into
371 REDCap by trained members of the study team. Clinical data will be retrieved from the patient’s
372 medical records and merged into REDCap or collected in a clinical entry interview with external
373 patients conducted by the study team and then entered into REDCap. Data quality is supported
374 by continuous monitoring, plausibility checks of the collected data and checks for missing
375 values by data managers. In addition, participants receive automated reminders from REDCap
376 to complete the questionnaires at T1 and T2, three and seven days after the initial invitation. If
377 the questionnaires remain incomplete, the study team contacts participants by phone two
378 weeks after the initial invitation. The study team also monitors adherence to the EMA questions
379 manually and contacts participants by phone if two consecutive days remain incomplete. Data
380 management and monitoring is performed by authorized and experienced study investigators
381 and project employees. In accordance with local laws and regulations, health-related data and
382 biological materials are stored for ten years after the publication of the research project. Only
383 authorized personnel have direct access to participant-level data and all electronic documents
384 are stored on UHB-maintained and regularly backed-up server. As soon as possible after data
385 collection all study-related documents are encoded, and participants are only identified by their
386 unique participant number. Personal data (i.e., phone numbers and e-mail addresses) will be
387 recorded in REDCap for the purpose of sending out the psychometric questionnaires and
388 EMAs at T1 and T2. Any study-related or participants’ personal data are only accessible for
389 authorized personnel (e.g., paper-based documentations are locked away in a research office).
390 Members of the study team conducting any research activity (e.g., data monitoring or using a
391 specific software) have been trained by senior members of the team and/or have completed a
392 training course and are acting on Standard Operating Procedures (SOPs) set by UHB or
393 developed by the team according to Good Clinical Practice (GCP).

394

395 **Potential Biases**

396 The inclusion of external participants requires a subjective attribution of persistent symptoms
397 to PCC or a confirmed PCC diagnosis. The diagnostic process of these instances may differ
398 from the diagnostic process of the specialized clinic in the UHB, potentially introducing more
399 heterogeneity into the sample. To address this potentially confounding variable, we will conduct
400 independent t-tests to investigate whether the three groups (subjective attribution, medical
401 diagnosis made outside or from the physicians from the UHB) differ in terms of
402 sociodemographic and diagnostic parameters. Since participation in the study is voluntary,
403 patients with high motivation, prosocial behavior, or mild or moderate PCC severity may

404 introduce a self-selection bias into the sample, as patients with more severe PCC may not
405 have the resources or energy to participate in the study, thereby potentially compromising the
406 generalizability of the results.

407

408 **Statistical Analysis**

409 Data will be analyzed in RStudio (46). Categorical data (e.g., sex) will be reported as counts
410 and percentages. Metric data (e.g., age) will be reported as means with standard deviations.
411 Primary analyses of longitudinal data include the calculation of generalized linear mixed
412 models (GLMMs) for psychometric, neurocognitive, and physical assessment data, and the
413 calculation of generalized additive mixed models (GAMMs) for EMAs. In both cases,
414 participants are included as a random effect and time as a fixed effect. A priori subgroups of
415 interest regarding interactions or effect modifying factors are sex, age, and duration of PCC
416 symptoms at BL. Additional covariates will be considered if suspected of confounding
417 influence. Secondary analyses include correlation analyses between EMAs and psychometric
418 questionnaires.

419 Missing data will be addressed using appropriate statistical methods, such as multiple
420 imputation, and is categorized into three groups: drop-out, lost-to-follow-up, and
421 discontinuation. Drop-out is defined as clear, participant-initiated, written, or verbal withdrawal
422 of consent before they complete the last data collection point (T3), in which case recorded
423 participant data is deleted upon request. Participants opting to drop out of the study cannot
424 reenter at a later point. Participants are discontinued from the study if they are not reachable
425 and/or refrain from communicating with the study team before any data collection. In case any
426 data was collected (e.g., blood samples from BL), they are declared lost-to-follow-up. Missing
427 data from discontinued participants will not be imputed. Participants are contacted at least four
428 times before they are informed that the study team is no longer trying to contact them to
429 schedule study-related appointments or remind them of adhering to study procedures.
430 Participants are firstly contacted by phone (with a message on the answering machine if the
431 call is not answered), secondly by mail, thirdly via phone again, and then, lastly, by an email
432 explaining that there will be no further contacting attempts. Depending on whether any data
433 were collected, the participants are then either declared lost-to-follow-up or discontinued from
434 the study.

435

436 **ETHICS AND DISSEMINATION**

437 The study has been approved by the Department of Clinical Research at University Hospital
438 Basel (ID: th22schaefer), the Ethics Commission of Northwest and Central Switzerland (ID:
439 2023-00359) and is registered at ClinicalTrials.gov (ID: NCT05781893). The first amendment to
440 this study protocol was submitted to the local ethics committee March 18, 2024, and accepted
441 March 22, 2024. The second amendment was submitted on June 3, 2024, and accepted June
442 18, 2024. Further amendments will be submitted to the appropriate bodies if needed. Key
443 results from this study will be published in peer-reviewed journals. The full protocol is
444 accessible through this manuscript. Study results are planned to be presented at conferences,
445 symposia, lectures, and presentations to the scientific community and the public.
446 Dissemination of results is additionally aligned within the consortium to optimize impact.
447 Authorship eligibility of this publication is based on the International Committee of Medical
448 Journal Editors (ICMJE) guidelines (47).

449

450 **Risks and Harm to Participants**

451 There is no additional effort except for additional blood samples and detailed data collection,
452 which requires cognitive and temporal efforts for the participants. Participants receive 50 Swiss
453 Francs as compensation for taking part in the study after completing T3, with a proportional
454 amount being paid out in case of withdrawal from the study. No intervention besides standard
455 care including individual remedies is given, no radiation is used, and no vulnerable group is
456 recruited. According to Human Research Ordinance (HRO) Art. 7 the risk category of this study
457 is "A". Adverse events and serious adverse events are reported according to HRO Art. 21 and
458 the appropriate bodies to be notified of safety and protective measures according to the Human
459 Research Act (HRA) Art. 15 and HRO Art. 20.

460

461 **Public and Patient Involvement**

462 The measurements and data collection instruments were chosen to adequately reflect the
463 range of PCC symptoms as presented by patients across the globe and informed by the newest
464 published research at the time of study development. The experiences and feedback from
465 patients treated in the PCC clinic at the UHB to date were taken into account when developing
466 and planning the study.

467

468 **Artificial Intelligence**

469 One author used Grammarly (48) for spell-checking this manuscript and two authors used
470 DeepL (49) to help translate study materials to English.

471

472 **Guidelines**

473 We used the Standardized Protocol Items Recommendations for Observational Studies
474 (SPIROS, 50) in the preparation of this protocol, and we will use the Strengthening the
475 Reporting of Observational Studies in Epidemiology (STROBE, 51) guidelines when reporting
476 the results of the study.

477

478 **Open Science**

479 There are currently no plans to grant public access to participant level data of this study.
480 Participant level data and pooled study data will be made available for consortium partners as
481 part of a joint controllership agreement. A copy of the informed consent form is available upon
482 request. The statistical codes will be made available upon request after analyses are
483 concluded.

484

485 **Acknowledgements**

486 The authors acknowledge the dedicated engagement and support of Julia Menges, Tabea
487 Rocco, Nadine Celine Grimm, Michèle Häner, and Lukas Ebner. Their feedback on the study
488 materials, inputs for planning and help in achieving core tasks in the study has been an
489 invaluable contribution. Further, the authors acknowledge the support of the master students
490 Aigerim Abdrakhim, Saskia Erni, Stefanie Meier, and Janik Hendry in the ongoing recruitment
491 of participants and their overall contribution to the study. The authors would like to extend their
492 gratitude to the doctors and general staff of the specialized PCC clinic for their efforts and
493 contributions towards the success of the study.

494

495 **Author Contribution Statement**

496 Contributions to this publication are structured according to the Contributor Roles Taxonomy
497 (CRediT;52). All authors have contributed, read, and approved the final version of the
498 manuscript.

499 Conceptualization: SR, ReS, GM, RaS, MM, KB, AM

500 Methodology: SR, ReS, GM, RaS, MM, KB, AM

501 Software: SR, ReS

502 Resources: SR, ReS, GM, RaS, MM, KB, AM

503 Writing - Original Draft: SR

504 Writing - Review and Editing: SR, ReS, GM, RaS, MM, KB, AM

505 Supervision: GM, RaS

506 Project administration: SR, ReS

507 Funding acquisition: GM, RaS, MM, KB, AM

508 **REFERENCES**

- 509 1. Coronavirus disease (COVID-19): Post COVID-19 condition [Internet]. 2021. Available
510 from: [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
511 [\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition).
- 512 2. Nittas V, Puhan M, Gao M, West E. Long COVID: Evolving Definitions, Burden of
513 Disease and Socio-Economic Consequences. Swiss School of Public Health. 2021.
- 514 3. Rochmawati E, Iskandar, A.C., & Kamilah, F. . Persistent symptoms among post-COVID-
515 19 survivors: A systematic review and meta-analysis. *J Clin Nurs*. 2024 Jan;33(1).
- 516 4. Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al. Long COVID
517 Through a Public Health Lens: An Umbrella Review. *Public Health Rev*. 2022;43.
- 518 5. de Bruijn S, van Hoek AJ, Mutubuki EN, Knoop H, Sloomweg J, Tulen AD, et al. Lower
519 prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
520 *Heliyon*. 03/30/2024;10(7).
- 521 6. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do
522 we know in 2023? *Polish archives of internal medicine*. 04/19/2023;133(4).
- 523 7. Nehme M, Vetter P, Chappuis F, Kaiser L, Guessous I, Nehme M, et al. Prevalence of
524 Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With
525 Negative Controls and Association With Vaccination Status. *Clin Infect Dis*.
526 2023;76(9):1567-75.
- 527 8. Perlis RH, Santilla M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al.
528 Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA network*
529 *open*. 10/03/2022;5(10).
- 530 9. Tene L, Bergroth T, Eisenberg A, Shapiro Ben David S, Chodick G. Risk factors, health
531 outcomes, healthcare services utilization, and direct medical costs of patients with long
532 COVID. *International journal of infectious diseases : IJID : official publication of the*
533 *International Society for Infectious Diseases*. 2023 Mar;128.
- 534 10. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al.
535 Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med*.
536 2022;28(8):1706-14.
- 537 11. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19.
538 *American journal of physiology Cell physiology*. 01/01/2022;322(1).
- 539 12. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms
540 and recommendations. *Nature Reviews Microbiology*. 2023;21(3):133-46.
- 541 13. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes.
542 *Nat Med*. 2022;28(5):911-23.
- 543 14. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of
544 COVID-19. *Science*. 2022;375(6585):1122-7.
- 545 15. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al.
546 Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19
547 (PASC) is accompanied by increased levels of antiplasmin. *Cardiovasc Diabetol*.
548 2021;20(1).
- 549 16. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al.
550 Autonomic dysfunction in 'long COVID': rationale, physiology and management
551 strategies. *Clin Med (Northfield Il)*. 2021;21(1):e63-e7.
- 552 17. Engelmann P, Reinke M, Stein C, Salzmann S, Löwe B, Toussaint A, et al. Psychological
553 factors associated with Long COVID: a systematic review and meta-analysis.
554 *eClinicalMedicine*. 2024;74:102756.
- 555 18. Allwang C, Frank T, Bruckmann P, Dinkel A, Binneboese M, Wallis H, et al. Addressing
556 psychosocial needs in patients with Long-COVID (PsyLoCo-Study): study protocol of a
557 pilot-study of a specialized modular intervention. *Frontiers in Psychiatry*. 2024;15.
- 558 19. Loft MI, Foged EM, Koreska M. An Unexpected Journey: The Lived Experiences of
559 Patients with Long-Term Cognitive Sequelae After Recovering from COVID-19. *Qual*
560 *Health Res*. 2022;32(8-9):1356-69.
- 561 20. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors,
562 and management. *BMJ*. 2021;374:n1648.

- 563 21. Parotto M, Gyöngyösi M, Howe K, Myatra SN, Ranzani O, Shakar-Hari M, et al. Post-
564 acute sequelae of COVID-19: understanding and addressing the burden of multisystem
565 manifestations. *The Lancet Respiratory medicine*. 2023 Aug;11(8).
- 566 22. CNS Vital Signs. <https://www.cnsvs.com/index.html>: CNS Vital Signs LLC.
- 567 23. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test
568 battery, CNS Vital Signs. *Arch Clin Neuropsychol*. 2006;21(7):623-43.
- 569 24. Crichton N. Visual analogue scale (VAS). *J Clin Nurs*. 2001;10(5):706-6.
- 570 25. Üstün TB, Kostanjsek N, Chatterji S, Rehm J. Measuring health and disability: Manual
571 for WHO disability assessment schedule WHODAS 2.0: World Health Organization;
572 2010.
- 573 26. Schmidt S, Mühlan H, Power M. The EUROHIS-QOL 8-item index: psychometric results
574 of a cross-cultural field study. *Eur J Public Health*. 2005;16(4):420-8.
- 575 27. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a New Measure for
576 Evaluating the Severity of Somatic Symptoms. *Psychosom Med*. 2002;64(2):258-66.
- 577 28. Toussaint A, Murray AM, Voigt K, Herzog A, Gierk B, Kroenke K, et al. Development and
578 Validation of the Somatic Symptom Disorder–B Criteria Scale (SSD-12). *Psychosom*
579 *Med*. 2016;78(1):5-12.
- 580 29. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a
581 measure of current depression in the general population. *J Affect Disord*.
582 2009;114(1):163-73.
- 583 30. Diagnostic and statistical manual of mental disorders: American Psychiatric Association;
584 2000.
- 585 31. Williams N. The GAD-7 questionnaire. *Occup Med*. 2014;64(3):224-.
- 586 32. Kocalevent R-D, Zenger M, Heinen I, Dwinger S, Decker O, Brähler E. Resilience in the
587 General Population: Standardization of the Resilience Scale (RS-11). *PLoS One*.
588 2015;10(11):e0140322.
- 589 33. Morin CM. Insomnia severity index. 1993.
- 590 34. Jackson C. The Chalder Fatigue Scale (CFQ 11). *Occup Med*. 2014;65(1):86-.
- 591 35. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc*
592 *Behav*. 1983;24(4):385-96.
- 593 36. Young Q-R, Ignaszewski A, Fofonoff D, Kaan A. Brief Screen to Identify 5 of the Most
594 Common Forms of Psychosocial Distress in Cardiac Patients: Validation of the
595 Screening Tool for Psychological Distress. *J Cardiovasc Nurs*. November-December
596 2007;22(6).
- 597 37. Ludwig K, Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-
598 5L. *Pharmacoeconomics*. 2018 Jun;36(6).
- 599 38. Herman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
600 preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life*
601 *research : an international journal of quality of life aspects of treatment, care and*
602 *rehabilitation*. 2011 Dec;20(10).
- 603 39. Meier BP, Konrath S, Fetterman AK, Dillard AJ, James C, Weinstein E, et al.
604 Development and Validation of the Single-Item Mindfulness Scale (SIMS). *J Pers*
605 *Assess*. 2022;105(6).
- 606 40. Zhang JW, Howell RT, Chen S, Goold AR, Bilgin B, Chai WJ, et al. 'I have high self-
607 compassion': A face-valid single-item self-compassion scale for resource-limited
608 research contexts. *Clin Psychol Psychother*. 2022 Jul;29(4).
- 609 41. Research Electronic Data Capture (REDCap). <https://www.project-redcap.org/>:
610 Vanderbilt University.
- 611 42. American Society for Surgery of the Hand. *The Hand: Examination and Diagnosis*. 2nd
612 ed: Churchill Livingstone, Edinburgh; 1983.
- 613 43. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute
614 walking tests in respiratory disease. *Br Med J (Clin Res Ed)*. 1982;284(6329):1607-8.
- 615 44. Borg G. Borg's perceived exertion and pain scales. Champaign, IL, US: Human Kinetics;
616 1998. viii, 104-viii, p.

- 617 45. Koufaki P, Mercer TH, Naish PF. Effects of exercise training on aerobic and functional
618 capacity of end-stage renal disease patients. Clin Physiol Funct Imaging.
619 2002;22(2):115-24.
- 620 46. Racine JS. RSTUDIO: A PLATFORM-INDEPENDENT IDE FOR R AND SWEAVE.
621 Journal of Applied Econometrics. 2012;27(1):167-72.
- 622 47. Editors ICoMJ. Recommendations for the Conduct, Reporting, Editing, and Publication
623 of Scholarly work in Medical Journals <https://www.icmje.org/recommendations/2024>
624 [updated 2024].
- 625 48. Grammarly - AI writing assistance <https://www.grammarly.com/>: Grammarly Inc.; 2009
626 [Available from: <https://www.grammarly.com/>].
- 627 49. DeepL - AI-assisted translations <https://www.deepl.com/de/translator>: DeepL SE; 2017
628 [Available from: <https://www.deepl.com/de/translator>].
- 629 50. Mahajan R, Burza S, Bouter LM, Sijtsma K, Knottnerus A, Kleijnen J, et al. Standardized
630 Protocol Items Recommendations for Observational Studies (SPIROS) for Observational
631 Study Protocol Reporting Guidelines: Protocol for a Delphi Study. JMIR Res Protoc.
632 2020;9(10):e17864.
- 633 51. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al.
634 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
635 statement: guidelines for reporting observational studies. Lancet (London, England).
636 10/20/2007;370(9596).
- 637 52. Credit Author Statement [Policy]. [https://www.elsevier.com/researcher/author/policies-
638 and-guidelines/credit-author-statement](https://www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-statement): Elsevier; [Available from:
639 [https://www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-
statement](https://www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-
640 statement)].

641